Lisette Rozeman's research on neo-adjuvant immunotherapy in melanoma patients is featured in this annual review as a remarkable milestone in clinical cancer research and care. Last year, this OpACIN-neo study showed that many melanoma patients with lymph node metastases could benefit from this treatment, which consists of immunotherapy (see video) before instead of after surgery.
The Netherlands Cancer Institute is highly active within the research field of neo-adjuvant immunotherapy. NKI researchers investigate this innovative treatment strategy in patients with different types of cancer: skin, intestine, breast, stomach, bladder, lung, renal cell, and head and neck cancer.
See and read more
- Last month Lisette Rozeman won the 2019 Antoni van Leeuwenhoek Award for her excellent research into immunotherapy for melanoma patients (see video)
- Read the news article about the OpACIN-neo study and the trend of neo-adjuvant immunotherapy here.
- Read the research paper here
- Check out this video to see how checkpoint inhibitors (immunotherapy) work